Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer.

The study aims at delivering a second WST09 treatment for the purpose of eradicating the localized prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: STEBA France

Criteria

Inclusion Criteria:

• Patients previously treated with WST09-mediated VTP, with a positive biopsy of the prostate 6 months following treatment

• Disease confined to the prostate

• Life expectancy greater than 5 years

Exclusion Criteria:

• Unwilling or unable to give informed consent

• Patients who have received another treatment for their prostate cancer since their previous WST09-mediated VTP